Mylan has announced that its subsidiary Matrix Laboratories has been notified by the World Health Organization (WHO) Prequalification of Medicines Programme that the WHO has withdrawn its notice of concern for Matrix Unit 8, which is located in the Vizianagaram District of India, with no remaining concerns outstanding.
Earlier in July, the WHO had reported considering to suspend products of Matrix at its manufacturing facility. It had also issued a Notice of Concern to Matrix Laboratories. The notice was issued following inspections at Vizianagaram manufacturing site.
Mylan, a diversified generics and specialty pharmaceutical company with a broad product portfolios, supported by a robust product pipeline.